Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

This study has been terminated.
Sponsor:
Collaborators:
German Hodgkin's Lymphoma Study Group
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by:
University of Cologne
ClinicalTrials.gov Identifier:
NCT00148018
First received: September 1, 2005
Last updated: July 9, 2008
Last verified: September 2006
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):